In Vitro Diagnostic Review Times Improving, FDA Reports
This article was originally published in The Gray Sheet
Executive Summary
The FDA device center's Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) has reduced its review times in nearly every premarket submission category, OIVD Deputy Director Donald St. Pierre told "The Gray Sheet" in a Dec. 8 interview